Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193375
Status:
COMPLETED
Last Update Posted:
2016-08-10
First Post:
2005-09-12
Brief Title:
Irinotecan Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of Concurrent Irinotecan Carboplatin and Radiation Therapy Followed by Bevacizumab Avastin in the Treatment of Patients With Limited Stage Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this multicenter trial we plan to evaluate the feasibility and toxicity of initial treatment with irinotecancarboplatinradiation therapy followed by treatment with bevacizumab in patients with limited stage small cell lung cancer
Detailed Description:
Upon determination of eligibility all patients will be receive
Irinotecan Carboplatin Radiation Therapy Bevacizumab
Patients will receive 4 courses of irinotecancarboplatin Radiation therapy will begin concurrently with the third course of chemotherapy The intervals between chemotherapy courses will be 21 days except for the interval between the third and fourth courses during radiation therapy which will be 28 days
Irinotecan Carboplatin Radiation Therapy Bevacizumab
Patients will receive 4 courses of irinotecancarboplatin Radiation therapy will begin concurrently with the third course of chemotherapy The intervals between chemotherapy courses will be 21 days except for the interval between the third and fourth courses during radiation therapy which will be 28 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None